This is truly a time to be optimistic about digital drug delivery. Our new research uncovers its many opportunities — but also illuminates some of the challenges that have surfaced with this new technology.
As an enabler of healthcare digital transformation, Molex is committed to helping pharmaceutical companies understand these trends, so they can navigate their own way to growth in this emergent area.
Where does digital drug delivery stand today? We interviewed 215 qualified professionals at pharmaceutical companies of all sizes in different parts of the world to find out.
88% of respondents believe digital drug delivery is either extremely or very important to their company’s future plans.
In fact, a third are already in the market with some form of:
There are a host of factors driving pharma’s interest or investment in digital drug delivery solutions, led by improved patient engagement, competitive advantage and ability to demonstrate better patient outcomes.
About that last point — 67% of those surveyed believe new delivery tech will either dramatically or notably improve patient outcomes.
Stakeholders expect many benefits from digital drug delivery. Topping the list was reduced overall costs of treatment through increased adherence to drug schedules (60%). Improved efficiency by targeting labor-intensive behavioral support (54%), and more efficient and scalable means of providing patient support (53%) rounded out the top three responses.
99% of our survey’s respondents said that their company will need external expertise in this critical endeavor, including safe and reliable production of devices, networking and connectivity, and data privacy and security help.
Molex is a recognized market leader in providing solutions for digital drug delivery devices. Working alongside our pharmaceutical partners, we are transforming the future and improving lives.